- Home
- OXBR vs IMRN Comparison
OXBR vs IMRN Comparison
Compare OXBR & IMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OXBR
- IMRN
- Stock Information
- Founded
- OXBR 2013
- IMRN 1994
- Country
- OXBR Cayman Islands
- IMRN Australia
- Employees
- OXBR N/A
- IMRN N/A
- Industry
- OXBR Property-Casualty Insurers
- IMRN Biotechnology: Pharmaceutical Preparations
- Sector
- OXBR Finance
- IMRN Health Care
- Exchange
- OXBR Nasdaq
- IMRN Nasdaq
- Market Cap
- OXBR 15.8M
- IMRN 15.0M
- IPO Year
- OXBR 2014
- IMRN N/A
- Fundamental
- Price
- OXBR $2.74
- IMRN $1.81
- Analyst Decision
- OXBR
- IMRN Strong Buy
- Analyst Count
- OXBR 0
- IMRN 1
- Target Price
- OXBR N/A
- IMRN $5.00
- AVG Volume (30 Days)
- OXBR 14.1K
- IMRN 6.2K
- Earning Date
- OXBR 11-13-2024
- IMRN 11-26-2024
- Dividend Yield
- OXBR N/A
- IMRN N/A
- EPS Growth
- OXBR N/A
- IMRN N/A
- EPS
- OXBR N/A
- IMRN N/A
- Revenue
- OXBR N/A
- IMRN $3,271,194.00
- Revenue This Year
- OXBR N/A
- IMRN N/A
- Revenue Next Year
- OXBR N/A
- IMRN N/A
- P/E Ratio
- OXBR N/A
- IMRN N/A
- Revenue Growth
- OXBR N/A
- IMRN 171.67
- 52 Week Low
- OXBR $0.87
- IMRN $1.59
- 52 Week High
- OXBR $3.72
- IMRN $5.96
- Technical
- Relative Strength Index (RSI)
- OXBR 52.49
- IMRN 35.96
- Support Level
- OXBR $2.41
- IMRN $1.73
- Resistance Level
- OXBR $2.97
- IMRN $1.99
- Average True Range (ATR)
- OXBR 0.22
- IMRN 0.12
- MACD
- OXBR -0.01
- IMRN 0.02
- Stochastic Oscillator
- OXBR 55.93
- IMRN 20.42
About OXBR Oxbridge Re Holdings Limited
Oxbridge Re Holdings Ltd is a specialty property and casualty reinsurer. It provides reinsurance solutions through its subsidiary. It focuses on underwriting fully collateralized reinsurance contracts primarily for property and casualty insurance companies in the Gulf Coast region of the United States, with an emphasis on Florida. Oxbridge specializes in underwriting medium frequency, high severity risks, where insufficient data exists to analyze effectively the risk/return profile of reinsurance contracts. The Company manages its business on the basis of one operating segment, Property and Casualty Reinsurance.
About IMRN Immuron Limited
Immuron Ltd is a clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.